Tafamidis ATTR denied as experimental or investigational by Humana?

Humana's specific coverage criteria for tafamidis attr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Tafamidis as "Experimental" — and Why This Denial Has a Strong Counter-Argument

Insurers are permitted to deny coverage for treatments they classify as experimental or investigational, meaning the insurer has determined the drug lacks sufficient evidence of clinical effectiveness for mainstream coverage. For tafamidis, this classification is particularly susceptible to challenge because the drug holds FDA approval specifically for ATTR cardiomyopathy — a regulatory milestone that typically takes a drug out of "experimental" status. Humana's experimental denial may reflect an outdated policy, a claim submitted under an unapproved off-label indication, or a policy that was written before the FDA approval and has not been updated. All three scenarios are appealable.

## Your Federal Appeal Rights

• ACA §2719 External Review: Experimental/investigational denials are specifically listed under federal law as eligible for external review by an Independent Review Organization (IRO). This is one of the most powerful appeal tools for this denial type. The window is generally approximately four months from the final internal denial — verify the exact date on your denial letter.
• ERISA §503: Full-and-fair review rights apply; Humana must provide the specific clinical basis and policy language behind the experimental classification in writing.
• Expedited Review: Simultaneously requestable if clinical urgency applies; typically resolved within 72 hours.

## Concrete Appeal Steps and Timeline

1. Obtain Humana's coverage policy for tafamidis and identify the exact language classifying it as experimental — is the policy dated before or after FDA approval? 2. Pull the FDA approval documentation for tafamidis (publicly available on FDA.gov) and compare the approved indication to the coded diagnosis on the claim. 3. File a Level 1 internal appeal attaching the FDA approval letter and the current prescribing information "Indications and Usage" section. 4. Request that the appeal be reviewed by a physician with relevant expertise (cardiologist or internist familiar with amyloidosis) — you have this right under ACA §2719. 5. If denied internally, proceed immediately to external IRO review, emphasizing the FDA-approval argument.

## Documentation to Gather

• FDA approval documentation: The approval letter and the "Indications and Usage" section of the current prescribing information — these are your primary exhibits.
• Diagnosis confirmation: ATTR-CM documentation (scintigraphy, biopsy, genetic testing) establishing that the claim is for the FDA-approved indication, not an off-label use.
• Prescriber letter: Confirms the on-label use and the medical rationale for this patient.
• Relevant cardiology society guidance: Generic reference to ACC/AHA or HFSA position statements that include tafamidis in their treatment algorithms — your cardiologist should draft this language.
• Humana's policy date: If the experimental classification predates FDA approval, document the discrepancy explicitly.

## Criteria-Mapping Structure

Your appeal cover letter should directly address Humana's experimental classification criteria one by one. Typical criteria include: Is the drug FDA-approved for this indication? (Yes — cite approval.) Is there adequate evidence from controlled studies? (Address generically by referencing the basis of the FDA approval, without quoting specific trial statistics.) Is the drug accepted in standard medical practice? (Reference guideline organization support generically.) A concise table answering each criterion with documentary evidence is the most effective format.